Evaluating the Use of KIM‐1 in Drug Development and Research Following FDA Qualification
Authors:
- 15 May 2018
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 104 (6) , 1175-1181
Abstract
The Biomarker Qualification Program was established at the Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA) to expedite the integration of promising biomarkers across multiple drug development programs. The first set of biomarkers qualified in 2008 consisted of seven nonclinical safety biomarkers for the detection of acute drug‐induced nephrotoxicity in rats, and included urinary kidney injury molecule‐1 (KIM‐1). This article discusses the use of KIM‐1 in drug development and research before and after CDER's qualification of KIM‐1. Use was determined by analyzing relevant documents identified by keyword searches using three databases: 1) an FDA internal database, Document Archiving, Reporting, and Regulatory Tracking System (DARRTS); 2) ClinicalTrials.gov; and 3) PubMed. The results indicate increased use of KIM‐1 as a biomarker for detection of kidney injury in drug development programs reviewed by CDER, as well as in research following qualification.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK110427)
This publication has 9 references indexed in Scilit:
- Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug developmentBritish Journal of Clinical Pharmacology, 2014
- Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage?Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2014
- Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing ConsortiumDrug Development Research, 2013
- Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing ConsortiumNature Biotechnology, 2010
- Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injuryNature Biotechnology, 2010
- Evolution of biomarker qualification at the health authoritiesNature Biotechnology, 2010
- Assay Validation for KIM-1: human urinary renal dysfunction biomarkerInternational Journal of Biological Sciences, 2009
- Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injuryAmerican Journal of Physiology-Renal Physiology, 2006
- Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injuryAmerican Journal of Physiology-Renal Physiology, 2004